The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus
NCT04591457
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Diabetes Mellitus
Interventions
DRUG:
Insulin Glargine Sansulin
DRUG:
Insulin Glargine Pen Injector [Lantus]
Sponsor
Indonesia University